Consensus Revolution Medicines, Inc.

Equities

RVMD

US76155X1000

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-28 pm EDT			5-day change	1st Jan Change
37.9 ^USD	-0.13%		-4.44%	+32.15%

May. 09	Wedbush Raises Price Target on Revolution Medicines to $46 From $42, Maintains Outperform Rating	MT
May. 08	Revolution Medicines Q1 Net Loss Narrows	MT

Evolution of the average Target Price on Revolution Medicines, Inc.

Price target over the last 5 years

History of analyst recommendation changes

2b22e7ddeb0.ykxdsRpO3TSRtTStxCalX--jHJsvh0vrTz3d1M-P618.hC487nYFn333jAH4smnzGaGQZNJCySm_Dnep45r7mjf6Px_ieTiQTKHxAA~8d919688cefb0a39a11827d963f18bac

Analyst Recommendations on Revolution Medicines, Inc.

Wedbush Raises Price Target on Revolution Medicines to $46 From $42, Maintains Outperform Rating	May. 09	MT
Oppenheimer Adjusts Revolution Medicines Price Target to $45 From $43, Maintains Outperform Rating	Apr. 12	MT
Needham Adjusts Revolution Medicines' Price Target to $46 From $36, Keeps Buy Rating	Apr. 12	MT
Piper Sandler Starts Revolution Medicines With Overweight Rating, $43 Price Target	Mar. 11	MT
HC Wainwright Raises Revolution Medicines Price Target to $44 From $28, Maintains Buy Rating	Mar. 08	MT
Wedbush Adjusts Revolution Medicines' Price Target to $42 From $41, Keeps Outperform Rating	Feb. 27	MT
Wedbush Starts Revolution Medicines With Outperform Rating, $41 Price Target	Jan. 04	MT
UBS Initiates Coverage on Revolution Medicines With Buy Rating, $40 Price Target	Dec. 20	MT
Raymond James Starts Revolution Medicines With Outperform Rating, Price Target is $30	Nov. 16	MT
Oppenheimer Raises Revolution Medicines Price Target to $43 From $40, Maintains Outperform Rating	23-10-23	MT
Needham Adjusts Revolution Medicines Price Target to $36 From $34, Maintains Buy Rating	23-10-23	MT
Stifel Raises Revolution Medicines' Price Target to $47 From $37, Keeps Buy Rating	23-09-21	MT
Needham Adjusts Price Target on Revolution Medicines to $34 From $35, Maintains Buy Rating	23-08-09	MT
Oppenheimer Adjusts Revolution Medicines Price Target to $40 From $35, Maintains Outperform Rating	23-08-02	MT
Needham Adjusts Price Target on Revolution Medicines to $35 From $31, Maintains Buy Rating	23-08-02	MT
Needham Adjusts Price Target on Revolution Medicines to $32 From $34, Maintains Buy Rating	23-05-09	MT
Goldman Sachs Adjusts Price Target on Revolution Medicines to $23 From $20, Maintains Neutral Rating	23-03-01	MT
Oppenheimer Adjusts Revolution Medicines Price Target to $35 From $30, Maintains Outperform Rating	23-02-28	MT
Needham Adjusts Revolution Medicines' Price Target to $38 From $32, Maintains Buy Rating	23-02-28	MT
JPMorgan Upgrades Revolution Medicines to Overweight From Neutral, Boosts Price Target to $38 From $32	23-02-28	MT
Needham Initiates Revolution Medicines at Buy Rating With $31 Price Target	22-12-14	MT
HC Wainwright Adjusts Revolution Medicines' Price Target to $32 From $30, Keeps Buy Rating	22-12-08	MT
HC Wainwright Adjusts Price Target on Revolution Medicines to $30 From $37, Maintains Buy Rating	22-11-08	MT
Oppenheimer Initiates Coverage on Revolution Medicines With Outperform Rating, $30 Price Target	22-10-21	MT
HC Wainwright Adjusts Revolution Medicines' Price Target to $37 From $40, Reiterates Buy Rating	22-08-17	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

37.9 USD

Average target price

44.82 USD

Spread / Average Target

+18.25%

High Price Target

48 USD

Spread / Highest target

+26.65%

Low Price Target

40 USD

Spread / Lowest Target

+5.54%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Revolution Medicines, Inc.

Wedbush
Oppenheimer
Needham & Co.
Piper Sandler
HC Wainwright
UBS
Raymond James
Stifel Nicolaus
Goldman Sachs
JPMorgan Chase
BofA Securities
Guggenheim
SVB Leerink
J.P. Morgan Chase

Ratings for Revolution Medicines, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar